These data suggest that SCAND1-MZF1 high expression is a better prognosis marker for patients suffering from pancreatic cancer and head and neck cancers, whereas SCAND1-MZF1 high expression is a poorer prognosis marker for patients suffering from kidney cancer. The gene discussed is SCAND1; the disease is pancreatic neoplasm.